L P Legakis1, L Karim-Nejad1, S S Negus2. 1. Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA. 2. Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, 23298, USA. sidney.negus@vcuhealth.org.
Abstract
RATIONALE: Synaptic neurotransmission with dopamine (DA), norepinephrine (NE), and serotonin (5-HT) is terminated primarily by reuptake into presynaptic terminals via the DA, NE, and 5-HT transporters (DAT/NET/SERT, respectively). Monoamine transporter inhibitors constitute one class of drugs used to treat both depression and pain, and therapeutic effects by these compounds often require repeated treatment for days or weeks. OBJECTIVES: The present study compared antinociceptive effects produced by repeated treatment with monoamine transporter inhibitors in a preclinical assay of pain-related depression of positively reinforced operant responding. METHODS: Adult Sprague-Dawley rats equipped with microelectrodes targeting a brain-reward area responded for pulses of electrical brain stimulation in an intracranial self-stimulation (ICSS) procedure. Intraperitoneal injection of dilute lactic acid served as a noxious stimulus that repeatedly depressed ICSS and also produced weight loss during 7 days of repeated acid administration. RESULTS: Acid-induced depression of both ICSS and body weight were completely blocked by repeated pretreatment with the nonsteroidal anti-inflammatory drug ketorolac. The DAT-selective inhibitor bupropion also fully blocked acid-induced ICSS depression and weight loss throughout all 7 days of treatment. The NET-selective inhibitor nortriptyline and the SERT-selective inhibitor citalopram were generally less effective, but both drugs blocked acid-induced ICSS depression by the end of the 7-day treatment. Acid-induced depression of ICSS and body weight were not blocked by the kappa opioid receptor (KOR) agonist U69593 or the KOR antagonist norbinaltorphimine. CONCLUSIONS: These results support effectiveness of bupropion to alleviate signs of pain-related behavioral depression in rats and further suggest that nortriptyline and citalopram produce significant but less reliable effects.
RATIONALE: Synaptic neurotransmission with dopamine (DA), norepinephrine (NE), and serotonin (5-HT) is terminated primarily by reuptake into presynaptic terminals via the DA, NE, and 5-HT transporters (DAT/NET/SERT, respectively). Monoamine transporter inhibitors constitute one class of drugs used to treat both depression and pain, and therapeutic effects by these compounds often require repeated treatment for days or weeks. OBJECTIVES: The present study compared antinociceptive effects produced by repeated treatment with monoamine transporter inhibitors in a preclinical assay of pain-related depression of positively reinforced operant responding. METHODS: Adult Sprague-Dawley rats equipped with microelectrodes targeting a brain-reward area responded for pulses of electrical brain stimulation in an intracranial self-stimulation (ICSS) procedure. Intraperitoneal injection of dilute lactic acid served as a noxious stimulus that repeatedly depressed ICSS and also produced weight loss during 7 days of repeated acid administration. RESULTS: Acid-induced depression of both ICSS and body weight were completely blocked by repeated pretreatment with the nonsteroidal anti-inflammatory drug ketorolac. The DAT-selective inhibitor bupropion also fully blocked acid-induced ICSS depression and weight loss throughout all 7 days of treatment. The NET-selective inhibitor nortriptyline and the SERT-selective inhibitor citalopram were generally less effective, but both drugs blocked acid-induced ICSS depression by the end of the 7-day treatment. Acid-induced depression of ICSS and body weight were not blocked by the kappa opioid receptor (KOR) agonist U69593 or the KOR antagonist norbinaltorphimine. CONCLUSIONS: These results support effectiveness of bupropion to alleviate signs of pain-related behavioral depression in rats and further suggest that nortriptyline and citalopram produce significant but less reliable effects.
Authors: Tarsis F Brust; Jenny Morgenweck; Susy A Kim; Jamie H Rose; Jason L Locke; Cullen L Schmid; Lei Zhou; Edward L Stahl; Michael D Cameron; Sarah M Scarry; Jeffrey Aubé; Sara R Jones; Thomas J Martin; Laura M Bohn Journal: Sci Signal Date: 2016-11-29 Impact factor: 8.192
Authors: Deniz Bagdas; Pretal P Muldoon; Shakir AlSharari; F Ivy Carroll; S Stevens Negus; M Imad Damaj Journal: Neuropharmacology Date: 2015-11-27 Impact factor: 5.250
Authors: Stephen M. Stahl; James F. Pradko; Barbara R. Haight; Jack G. Modell; Carol B. Rockett; Susan Learned-Coughlin Journal: Prim Care Companion J Clin Psychiatry Date: 2004
Authors: S Stevens Negus; Ember M Morrissey; Marisa Rosenberg; K Cheng; Kenner C Rice Journal: Psychopharmacology (Berl) Date: 2010-01-26 Impact factor: 4.530
Authors: Dana E Selley; Matthew F Lazenka; Laura J Sim-Selley; Julie R Secor McVoy; David N Potter; Elena H Chartoff; William A Carlezon; S Stevens Negus Journal: Neuropharmacology Date: 2020-01-07 Impact factor: 5.250
Authors: David J Reiner; E Andrew Townsend; Javier Orihuel; Sarah V Applebey; Sarah M Claypool; Matthew L Banks; Yavin Shaham; S Stevens Negus Journal: Psychopharmacology (Berl) Date: 2021-03-25 Impact factor: 4.530
Authors: C Austin Zamarripa; Tanya Pareek; Hayley M Schrock; Thomas E Prisinzano; Bruce E Blough; Kenneth J Sufka; Kevin B Freeman Journal: Psychopharmacology (Berl) Date: 2021-08-25 Impact factor: 4.530
Authors: A N Baldwin; M L Banks; S A Marsh; E A Townsend; M Venniro; Y Shaham; S Stevens Negus Journal: Psychopharmacology (Berl) Date: 2022-01-19 Impact factor: 4.530